Adam J. Lamble

Hematology | Oncology

4800 Sand Point Way NE
Seattle, WA 98105

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Plasticity under pressure: biology and detection of lineage switch in acute leukemia.

Plasticity under pressure: biology and detection of lineage switch in acute leukemia.

Journal: Leukemia

Published: February 25, 2026

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 09, 2026

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

Journal: Nature reviews. Clinical oncology

Published: December 15, 2025

Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

Journal: Blood advances

Published: December 08, 2025

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.

Journal: Blood advances

Published: December 08, 2025

Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?

Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.

Journal: Blood advances

Published: October 01, 2025

Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL.

Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL.

Journal: Journal for immunotherapy of cancer

Published: August 22, 2025

Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 14, 2025

Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement.

Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement.

Journal: HemaSphere

Published: June 09, 2025

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

Journal: Blood advances

Published: May 06, 2025

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 28, 2025

Showing 1-12 of 50

Last Updated: 09/26/2026